Member News
-
Fineqia Appoints Arnaud Goubely as Head of Risk and Compliance
January 11, 2024 (Source) — Fineqia International Inc. (the “Company” or “Fineqia”) (CSE: FNQ) (OTC: FNQQF) (Frankfurt: FNQA),…
-
Appia Receives Approval for 12 Additional Claim Blocks at Its PCH Rare Earths Ionic Adsorption Clay Project, Goias, Brazil
Total Exploration Area More Than Doubled Adding 23,412.11 Hectares, Presenting Exceptional New Potential for Additional Critical Mineral Targets…
-
Nano One Announces Carlo Valente as CFO
Highlights: Carlo Valente recruited as CFO effective Jan 15, 2024. Adds significant growth expertise. Dan Martino remains with…
-
Quantum eMotion Announces the Creation of Quantum eHealth, a New Subsidiary Focused on Healthcare Cybersecurity Applications
January 10, 2024 (Source) — Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (“QeM” or the “Company”), a pioneering…
-
Digital Asset-Based Exchange Traded Funds (ETFs) and Notes (ETNs) AUM Grew 2.5x in 2023 to Nearly $50 Bln
January 10, 2024 (Source) — Fineqia International Inc. (the “Company” or “Fineqia”) (CSE: FNQ) (OTC: FNQQF) (Frankfurt: FNQA),…
-
FendX Completes Second Pilot Run to Manufacture REPELWRAP(TM) Film Using Dunmore’s Commercial Equipment
January 10, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a nanotechnology…
-
NEO Battery Materials Provides Letter to Shareholders – 2024 Strategy & Outlook
January 09, 2024 (Source) — (TSXV: NBM) (OTCQB: NBMFF) NEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost…
-
Auxico Announces Results of a 2023 Sampling Campaign on the Minastyc Property
January 9, 2024 (Source) — Auxico Resources Canada Inc. (CSE: AUAG), (OTCQB: AUXIF) (the “Company” or “Auxico”) is pleased…
-
Critical Metals PLC Notice of AGM / Board Changes and Extension of Warrant Term
January 9, 2024 (Source) — Critical Metals plc, a mining company established to acquire mining opportunities in the…
-
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
January 9, 2024 (Source) — Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences…
